Rheumatology · 12 h ago
Thrombosis prevention in early systemic lupus remains uncertain
A Nature Reviews Rheumatology article highlights the clustering of thrombotic events around systemic lupus erythematosus (SLE) onset, particularly among patients with antiphospholipid antibodies. The authors argue that randomized trials are needed to assess whether early primary prevention could reduce risk.
- Thrombosis risk clusters near SLE onset.
- Risk is highlighted in patients with antiphospholipid antibodies.
- Primary prevention remains an open research question.
- Randomized trials are needed.
Thrombotic events occur around the onset of systemic lupus erythematosus, especially in patients with antiphospholipid antibodies. In this article, Larsen and Troldborg discuss the timing of thrombosis risk and the limits of current prevention approaches; the supplied text does not describe a new study or provide sample-size data.
The authors note that effective thromboprophylaxis is largely confined to secondary prevention and propose that an early thrombo-inflammatory window might offer an opportunity for primary prevention. They call for randomized trials to test this possibility. The article is a perspective rather than trial evidence, and the available text provides no new estimates of risk or evidence that early preventive treatment improves outcomes.
Is this summary clinically accurate?
Help fellow clinicians: your rating sends inaccurate summaries straight to our editors.
Sign in to rate this summary →Source
Nature Reviews Rheumatology: Rethinking thrombosis prevention in systemic lupus erythematosus ↗This is an automated AI-condensed summary that has not yet been reviewed by an editor. Always consult the full item at the original source.